Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall ppaOver 2,500 PPA lawsuits have been filed against drug manufacturers of cough, cold, and diet pills that contained PPA. The first few of the numerous PPA lawsuits are now being decided on. Mainly, the drug companies have continued to dispute the 1999 study that led to the FDA decision to recommend PPA''s removal.
Available for decades, PPA was found in a great number of over-the-counter-products used widely by adults and children. The study was commissioned by PPA producing drug companies years after evidence continued to surface indicating risks of hemorrhagic stroke, the deadliest form of a stroke. The FDA mandated the study occur and the drug companies commissioned Yale to take part in the epidemiologic study that cost $5 million and lasted five years.
The PPA lawsuits reference the Yale study, though the PPA lawsuits filed prior to the Yale study findings going public have had more difficulty arguing the case. Due to the ongoing PPA lawsuits, internal company documents have been obtained, showing evidence that instead of immediately alerting the public about the Yale links between PPA and stroke, attempts to keep it quiet and stall government regulation occurred.
It was not for 13 months after the Yale study was completed that the FDA recommended the removal of PPA from over 100 PPA products. When the FDA receive much criticism for its delay and allowing hundreds of more strokes to be suffered, the agency responded by saying they did not move faster because the drug industry''s attempts to discredit the study. The failure for an immediate PPA removal has also been the source of PPA lawsuits.
Even after the agency stepped in, a survey that was commissioned by PPA lawsuits plaintiffs estimated 3.5 million U.S. households still had PPA containing products 15 months after the November 2000 removal request. The PPA industry has continued to argue against its own commissioned study to defend their products in PPA lawsuits. These PPA lawsuits have been filed against the world''s largest drug companies.
Pharmaceutical company lawyers suggest the Yale study attempted to show the correlation between PPA and stroke in order to have it published. This argument is disputed in PPA lawsuits considering the companies approved protocol and handpicked investigators that had already shown doubt in links between PPA and stroke. In a PPA lawsuit that attempted to prove the study unreliable the judge chastised the arguments and defended the quality of the research.
Hemorrhagic stroke kills more than a third of all victims within a month and leaves more than a third of survivors severely disabled. PPA lawsuits allege the drug industry spent over twenty years fighting off the growing evidence of the risks of PPA and hemorrhagic stroke while unknowing consumers continued to purchase the products. Women have been found to have the highest risk of suffering hemorrhagic stroke because of PPA products, according to the Yale University study. The risk of suffering a stroke because of PPA was especially dangerous because of the inability to predict who was at risk for the potentially deadly effects.
In November 2000, the FDA asked companies using PPA (phenlypropanolamine) in their cold products to voluntarily take the products off the market because of possible health risks, including links with hemorrhagic stroke in first time female users. Now,...